Urate lowering therapy is associated with a lower risk of heart failure hospitalisation or mortality in hyperuricaemic patients with heart failure: a comparative effectiveness study

Back

ESC Premium Access

Urate lowering therapy is associated with a lower risk of heart failure hospitalisation or mortality in hyperuricaemic patients with heart failure: a comparative effectiveness study

Session: Biomarkers to improve prognostication in heart failure: what's new?

Topic: Pharmacotherapy

Speaker: Mr S. Kiddle (Cambridge, GB)

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

Add to my library

About the speaker

Mr Steven Kiddle

AstraZeneca, Cambridge (United Kingdom of Great Britain & Northern Ireland)

0 follower

4 more presentations in this session

Additive prognostic value of cardiac biomarkers in patients with chronic obstructive pulmonary disease and heart failure

Speaker: Doctor G. Vergaro (Pisa, IT)

Cysteine-rich angiogenic inducer 61 (CCN1) independently predicts all-cause mortality in patients with dilated cardiomyopathy

Speaker: Doctor R. Klingenberg (Bad Nauheim, DE)

Discharge FGF23 levels predicts one year outcome in patients admitted with acute heart failure

Speaker: Doctor G. Vergaro (Pisa, IT)

Endotrophin is significantly associated with disease severity and increased risk of adverse outcome in HFpEF but not in HFrEF patients

Speaker: Doctor A. Reese-Petersen (Copenhagen, DK)

Access the full session

Biomarkers to improve prognostication in heart failure: what's new?

Speakers: Mr S. Kiddle, Doctor G. Vergaro, Doctor R. Klingenberg, Doctor G. Vergaro, Doctor A. Reese-Petersen

Access

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources